Qiagen N.V. (0RLT.IL)
| Previous close | 43.54 |
| Open | 39.03 |
| Bid | 40.34 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 38.66 - 39.06 |
| 52-week range | 33.78 - 48.18 |
| Volume | |
| Avg. volume | 228,587 |
| Market cap | 9.549B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 28.73 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
QIAGEN N.V. to release results for Q1 2024 and hold webcast
Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024. Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining the conference call Register for call back connection - C
- Globe Newswire
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
Novel QIAcuity dPCR PanCancer Kits can detect rare mutations of EGFR and BRAF genes at the same time, while saving sample material, reducing time and cost // New QIAseq Targeted RNA-seq Panel for T-cell Receptor allows targeted next-generation sequencing of T-cell receptors, increasing accuracy and sensitivity PAXgene® Urine Liquid Biopsy Set to enable non-invasive sample collection and cell-free DNA stabilization, thereby allowing researchers to make advances in urine liquid biopsyVenlo, the Ne
- Globe Newswire
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced epidemiology dashboards and improved remote system management // Growing global presence: Over 4,000 QIAstat-Dx instruments for reliable, fast and cost‑effective diagnosis of complex syndromes placed worldwide by the end of 2023Venlo, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: Q
